Evidence map›Paper›PMID 36034404›Full record

ArticlePulmonary circulation2022

Pulmonary Vascular Research Institute GoDeep: A meta-registry merging deep phenotyping datafrom international PH reference centers.

Raphael W Majeed, Martin R Wilkins, Luke Howard, Paul M Hassoun, Anastasia Anthi, Hector R Cajigas, John Cannon, Stephen Y Chan, Victoria Damonte, Jean Elwing and 30 more

Registry-linked trialAbstract read
In one paragraph

Article in Pulmonary circulation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05329714 (PVRI Global Deep Phenotyping Meta-Registry for Pulmonary Hypertension), which is not on this map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05329714 recruitingnot on this map

PVRI Global Deep Phenotyping Meta-Registry for Pulmonary Hypertension

TypeobservationalSponsorUniversity of GiessenRan2020 to 2055Enrolled40,000ConditionsPulmonary Hypertension, Global Health
3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors.

Raphael W MajeedDepartment of Internal Medicine Universities of Giessen and Marburg Lung Center (UGMLC), German Center for Lung Research (DZL) Giessen Germany.ORCID 0000-0002-8260-8815
Martin R WilkinsNational Heart and Lung Institute and Imperial College London NHS Healthcare Trust London UK.
Luke HowardNational Heart and Lung Institute and Imperial College London NHS Healthcare Trust London UK.
Paul M HassounDepartment of Medicine Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine Baltimore Maryland USA.
Anastasia Anthi1st Department of Critical Care National & Kapodistrian University of Athens Medical School and Pulmonary Hypertension Clinic, Evangelismos General Hospital Athens Greece.
Hector R CajigasDivision of Pulmonary and Critical Care Medicine Mayo Clinic Rochester New York USA.
John CannonPulmonary Vascular Diseases Unit, Royal Papworth Hospital, Cambridge Biomedical Campus Cambridge UK.
Stephen Y ChanDepartment of Medicine, Division of Cardiology, Center for Pulmonary Vascular Biology and Medicine, Pittsburgh Heart, Lung, Blood, and Vascular Medicine Institute University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center Pittsburgh Pennsylvania USA.ORCID 0000-0002-9520-7527
Victoria DamonteHospital de Niños, Hospital Privado Universitario, Clinica Universitaria Reina Fabiola and Instituto Oulton-Catholic, University of Córdoba Córdoba Argentina.
Jean ElwingDivision of Pulmonary, Critical Care and Sleep Medicine University of Cincinnati College of Medicine Cincinnati Ohio USA.
Kai FörsterLudwig-Maximilians University of Munich Munchen Germany.
Robert FrantzDepartment of Cardiology Mayo Clinic Rochester New York USA.ORCID 0000-0003-4128-3978
Stefano GhioFondazione IRCCS Policlinico S.Matteo Pavia Italy.
Imad Al GhoulehDepartment of Medicine, Division of Cardiology, Center for Pulmonary Vascular Biology and Medicine, Pittsburgh Heart, Lung, Blood, and Vascular Medicine Institute University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center Pittsburgh Pennsylvania USA.
Anne HilgendorffLudwig-Maximilians University of Munich Munchen Germany.
Arun JoseDivision of Pulmonary, Critical Care and Sleep Medicine University of Cincinnati College of Medicine Cincinnati Ohio USA.ORCID 0000-0001-7109-2692
Ernesto JuanedaHospital de Niños, Hospital Privado Universitario, Clinica Universitaria Reina Fabiola and Instituto Oulton-Catholic, University of Córdoba Córdoba Argentina.
David G KielySheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital and University of Sheffield Sheffield UK.
Allan LawrieSheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital and University of Sheffield Sheffield UK.ORCID 0000-0003-4192-9505
Stylianos E Orfanos1st Department of Critical Care National & Kapodistrian University of Athens Medical School and Pulmonary Hypertension Clinic, Evangelismos General Hospital Athens Greece.
Antonella PepeFondazione IRCCS Policlinico S.Matteo Pavia Italy.
Joanna Pepke-ZabaPulmonary Vascular Diseases Unit, Royal Papworth Hospital, Cambridge Biomedical Campus Cambridge UK.
Yuriy SirenkoDepartment of Symptomatic Hypertension "National Scientific Center 'The M.D. Strazhesko Institute of Cardiology'" of National Academy of Medical Science Kyiv Ukraine.
Andrew J SwettDivision of Pulmonary, Allergy, and Critical Care, and Vera Moulton Wall Center for Pulmonary Vascular Disease Stanford University Stanford California USA.
Olena TorbasDepartment of Symptomatic Hypertension "National Scientific Center 'The M.D. Strazhesko Institute of Cardiology'" of National Academy of Medical Science Kyiv Ukraine.
Roham T ZamanianDivision of Pulmonary, Allergy, and Critical Care, and Vera Moulton Wall Center for Pulmonary Vascular Disease Stanford University Stanford California USA.
Kurt MarquardtDepartment of Internal Medicine Universities of Giessen and Marburg Lung Center (UGMLC), German Center for Lung Research (DZL) Giessen Germany.
Achim Michel-BackofenDepartment of Internal Medicine Universities of Giessen and Marburg Lung Center (UGMLC), German Center for Lung Research (DZL) Giessen Germany.
Tobiah AntoineDepartment of Internal Medicine Universities of Giessen and Marburg Lung Center (UGMLC), German Center for Lung Research (DZL) Giessen Germany.
Jochen WilhelmInstitute for Lung Health (ILH), Cardio-Pulmonary Institute (CPI) Giessen Germany.
Stephanie BarwickPulmonary Vascular Research Institute (PVRI) Canterbury UK.
Phillipp KriebDepartment of Internal Medicine Universities of Giessen and Marburg Lung Center (UGMLC), German Center for Lung Research (DZL) Giessen Germany.
Meike FuenderichDepartment of Internal Medicine Universities of Giessen and Marburg Lung Center (UGMLC), German Center for Lung Research (DZL) Giessen Germany.
Patrick FischerDepartment of Internal Medicine Universities of Giessen and Marburg Lung Center (UGMLC), German Center for Lung Research (DZL) Giessen Germany.
Henning GallDepartment of Internal Medicine Universities of Giessen and Marburg Lung Center (UGMLC), German Center for Lung Research (DZL) Giessen Germany.ORCID 0000-0001-7016-7373
Hossein-Ardeschir GhofraniDepartment of Internal Medicine Universities of Giessen and Marburg Lung Center (UGMLC), German Center for Lung Research (DZL) Giessen Germany.
Friedrich GrimmingerDepartment of Internal Medicine Universities of Giessen and Marburg Lung Center (UGMLC), German Center for Lung Research (DZL) Giessen Germany.
Khodr TelloDepartment of Internal Medicine Universities of Giessen and Marburg Lung Center (UGMLC), German Center for Lung Research (DZL) Giessen Germany.
Manuel J RichterDepartment of Internal Medicine Universities of Giessen and Marburg Lung Center (UGMLC), German Center for Lung Research (DZL) Giessen Germany.
Werner SeegerDepartment of Internal Medicine Universities of Giessen and Marburg Lung Center (UGMLC), German Center for Lung Research (DZL) Giessen Germany.ORCID https://orcid.org/0000-0003-1946-0894

Funding

Endothelial Reprogramming in Pulmonary HypertensionR01HL148712 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI AL GHOULEH, IMAD · 2019 to 2023
$1.9M
Reclassifying Pulmonary Arterial Hypertension Into Immune Phenotypes Using Machine LearningK23HL151892 · NHLBI · STANFORD UNIVERSITY · PI SWEATT, ANDREW JOHN · 2020 to 2024
$942k
Biomarker Discovery in Portopulmonary HypertensionK23HL164971 · NHLBI · UNIVERSITY OF CINCINNATI · PI Arun Jose · 2023 to 2026
$822k
NHLBI NIH HHS K23 HL151892NHLBI NIH HHS K23 HL164971NHLBI NIH HHS R01 HL148712
6 · The paper itself

Abstract

The Pulmonary Vascular Research Institute GoDeep meta-registry is a collaboration of pulmonary hypertension (PH) reference centers across the globe. Merging worldwide PH data in a central meta-registry to allow advanced analysis of the heterogeneity of PH and its groups/subgroups on a worldwide geographical, ethnical, and etiological landscape (ClinTrial. gov NCT05329714). Retrospective and prospective PH patient data (diagnosis based on catheterization; individuals with exclusion of PH are included as a comparator group) are mapped to a common clinical parameter set of more than 350 items, anonymized and electronically exported to a central server. Use and access is decided by the GoDeep steering board, where each center has one vote. As of April 2022, GoDeep comprised 15,742 individuals with 1.9 million data points from eight PH centers. Geographic distribution comprises 3990 enrollees (25%) from America and 11,752 (75%) from Europe. Eighty-nine perecent were diagnosed with PH and 11% were classified as not PH and provided a comparator group. The retrospective observation period is an average of 3.5 years (standard error of the mean 0.04), with 1159 PH patients followed for over 10 years. Pulmonary arterial hypertension represents the largest PH group (42.6%), followed by Group 2 (21.7%), Group 3 (17.3%), Group 4 (15.2%), and Group 5 (3.3%). The age distribution spans several decades, with patients 60 years or older comprising 60%. The majority of patients met an intermediate risk profile upon diagnosis. Data entry from a further six centers is ongoing, and negotiations with >10 centers worldwide have commenced. Using electronic interface-based automated retrospective and prospective data transfer, GoDeep aims to provide in-depth epidemiological and etiological understanding of PH and its various groups/subgroups on a global scale, offering insights for improved management.

Indexed as

deep phenotypingmeta‐registryoutcomepulmonary hypertensionrisk assessmentworldwide outreach

Identifiers

PMID36034404
PMCPMC9399782

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.